$SRNE took this post from a yahoo board member: Chris has some valid points I have taken this opportunity last week to double down on SRNE for the following reasons: 1) SRNE has cancelled the $250M ATM for issuing new shares at a point when it has tremendous expenses in R&D. This means that some large pharmaceutical company is funding SRNE. Possible takeover target when the results start rolling in. 2) SRNE bought two companies by providing SRNE shares to the shareholders of the companies. Why would these shareholders take a chance in selling their companies by only accepting shares unless they were presented data that are promising not just in the testing but also the backing of SRNE by large pharma and investors. 3) Large increase in major holdings of serious mutual and hedge funds of SRNE shares. (Follow the money)
  • 11
11 Likes